HomeCompareINNMF vs PLD

INNMF vs PLD: Dividend Comparison 2026

INNMF yields 1081.08% · PLD yields 3.18%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 INNMF wins by $37306281.68M in total portfolio value
10 years
INNMF
INNMF
● Live price
1081.08%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37306288.18M
Annual income
$31,563,031,594,132.85
Full INNMF calculator →
PLD
PLD
● Live price
3.18%
Share price
$128.78
Annual div
$4.10
5Y div CAGR
74.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6.50M
Annual income
$5,256,436.18
Full PLD calculator →

Portfolio growth — INNMF vs PLD

📍 INNMF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodINNMFPLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, INNMF + PLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
INNMF pays
PLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

INNMF
Annual income on $10K today (after 15% tax)
$91,891.89/yr
After 10yr DRIP, annual income (after tax)
$26,828,576,855,012.92/yr
PLD
Annual income on $10K today (after 15% tax)
$270.62/yr
After 10yr DRIP, annual income (after tax)
$4,467,970.75/yr
At 15% tax rate, INNMF beats the other by $26,828,572,387,042.17/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of INNMF + PLD for your $10,000?

INNMF: 50%PLD: 50%
100% PLD50/50100% INNMF
Portfolio after 10yr
$18653147.34M
Annual income
$15,781,518,425,284.51/yr
Blended yield
84.61%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PLD right now

INNMF
No analyst data
Altman Z
45.4
Piotroski
2/9
PLD
Analyst Ratings
25
Buy
16
Hold
1
Sell
Consensus: Buy
Price Target
$136.00
+5.6% upside vs current
Range: $119.00 — $155.00
Altman Z
1.9
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

INNMF buys
0
PLD buys
0
No recent congressional trades found for INNMF or PLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricINNMFPLD
Forward yield1081.08%3.18%
Annual dividend / share$2.00$4.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%74.4%
Portfolio after 10y$37306288.18M$6.50M
Annual income after 10y$31,563,031,594,132.85$5,256,436.18
Total dividends collected$36872092.59M$6.37M
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: INNMF vs PLD ($10,000, DRIP)

YearINNMF PortfolioINNMF Income/yrPLD PortfolioPLD Income/yrGap
1← crossover$118,808$108,108.11$11,255$555.24+$107.6KINNMF
2$1,327,510$1,200,385.03$13,062$1,018.59+$1.31MINNMF
3$13,955,553$12,535,117.70$15,903$1,926.67+$13.94MINNMF
4$138,087,992$123,155,549.73$20,839$3,823.32+$138.07MINNMF
5$1,286,637,044$1,138,882,892.71$30,464$8,166.08+$1286.61MINNMF
6$11,294,046,827$9,917,345,190.59$52,054$19,457.30+$11293.99MINNMF
7$93,443,552,038$81,358,921,932.82$109,886$54,188.93+$93443.44MINNMF
8$729,086,740,275$629,102,139,594.15$304,030$186,451.18+$729086.44MINNMF
9$5,367,529,524,068$4,587,406,711,974.06$1,166,125$840,813.32+$5367528.36MINNMF
10$37,306,288,184,886$31,563,031,594,132.85$6,504,190$5,256,436.18+$37306281.68MINNMF

INNMF vs PLD: Complete Analysis 2026

INNMFStock

Amplia Therapeutics Limited, a pharmaceutical company, focuses on development of focal adhesion kinase (FAK) inhibitors for oncology and chronic fibrosis in Australia. The company's product pipeline includes AMP945, an inhibitor of FAK, for pancreatic cancer and idiopathic pulmonary fibrosis, as well as other cancers and fibrotic diseases indications, that has completed Phase I clinical trial; and AMP886 for cancer and fibrotic disease indication. It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.

Full INNMF Calculator →

PLDREIT

Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. As of December 31, 2020, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 984 million square feet (91 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 5,500 customers principally across two major categories: business-to-business and retail/online fulfillment.

Full PLD Calculator →
📬

Get this INNMF vs PLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

INNMF vs SCHDINNMF vs JEPIINNMF vs OINNMF vs KOINNMF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.